Related Experiment Videos

Fluoxetine and reversal of multidrug resistance

Dan Peer1, Rimona Margalit

  • 1Department of Biochemistry, George S. Wise Life Science Faculty, Tel Aviv University, Tel Aviv 69978, Israel

Cancer Letters
|July 15, 2005
PubMed

Insights

The antidepressant fluoxetine (Prozac) shows potential in overcoming cancer multidrug resistance (MDR). It acts as a multi-pump agent, suggesting its use as a novel fourth-generation chemosensitizer.

Area of Science:

  • Oncology
  • Pharmacology
  • Cancer Research

Background:

  • Multidrug resistance (MDR) is a major challenge in cancer chemotherapy.
  • ATP-binding cassette (ABC) transporters and cancer stem cells contribute to MDR.
  • Existing MDR reversal agents (chemosensitizers) have limitations.

Purpose of the Study:

  • To review recent findings on using fluoxetine to modulate cancer MDR.
  • To evaluate fluoxetine as a potential fourth-generation chemosensitizer.
  • To discuss the mechanisms of MDR and chemosensitization.

Main Methods:

  • Review of in vitro and in vivo studies on fluoxetine's MDR-modulating effects.
  • Analysis of fluoxetine's mechanism as a single-pump or multi-pump agent.
  • Examination of experimental criteria for novel chemosensitizer candidates.

Main Results:

  • Fluoxetine demonstrates chemosensitizing activity against multidrug-resistant cancer cells.
  • Fluoxetine functions as a multi-pump MDR reversal agent.
  • Evidence supports considering fluoxetine a fourth-generation chemosensitizer.

Conclusions:

  • Fluoxetine shows promise for overcoming cancer multidrug resistance.
  • Further clinical investigation of fluoxetine for MDR modulation is warranted.
  • Development of novel chemosensitizers remains a critical need in cancer therapy.

Related Concept Videos

Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs01:28

Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs

Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Antidepressant Drugs: Overview01:25

Antidepressant Drugs: Overview

Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists01:23

Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists

Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
Desensitization and Tachyphylaxis01:20

Desensitization and Tachyphylaxis

Tachyphylaxis is described as a rapid decrease in response to a drug after repeated or continuous administration of the same drug dose. It is a phenomenon where the body becomes less responsive to a particular substance or intervention over time, requiring higher doses or stronger interventions to achieve the same effect. It results from adaptive changes in the body's receptors, signaling pathways, or physiological processes that occur in response to prolonged exposure to a stimulus.
Several...